XML 41 R29.htm IDEA: XBRL DOCUMENT
v3.21.2

Research Collaboration and License Agreements - Additional Information (Details) | 1 Months Ended | 6 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Nov. 30, 2017 USD ($) Target | Jun. 30, 2021 USD ($) | Jun. 30, 2020 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Jul. 31, 2019 USD ($)
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |
Revenue recognized on research collaboration and license agreements |  | $ 11,100,000 |  |  |  |  |  |
Changes in deferred revenue due to additions to deferred revenue |  | (8,075,431) | $ (7,952,998) |  |  |  |  |
Unsatisfied performance obligations expected to be recognized as revenue |  | 37,000,000.0 |  |  |  |  |  |
Bayer Collaboration Agreement |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved or options for all targets exercised |  |  |  |  |  |  |  | $ 17,500,000
Changes in deferred revenue due to additions to deferred revenue |  | 3,000,000.0 |  |  |  |  |  |
Bayer Collaboration Agreement | Research Funding Payments |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved or options for all targets exercised |  | 3,000,000.0 | $ 3,000,000.0 |  |  |  |  | $ 1,500,000
Bayer Collaboration Agreement | Research Funding Payments | Scenario Forecast |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved or options for all targets exercised |  |  |  |  | $ 10,500,000 |  |  |
Bayer Collaboration Agreement | Stock Purchase Agreement |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |
Fair value of the shares sold |  | 2,900,000 |  |  |  |  |  |
Additional consideration received |  | 2,900,000 |  |  |  |  |  |
Pfizer, Inc. |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |
Upfront non-refundable payment and certain additional payments received |  |  |  | $ 28,000,000.0 |  |  |  |
Pfizer, Inc. | Option Exercised |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved or options for all targets exercised |  | $ 4,900,000 |  |  |  |  |  |
Pfizer, Inc. | Substitution Target Payments |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved or options for all targets exercised |  |  |  |  |  | $ 3,000,000.0 | $ 1,200,000 |
Genentech, Inc. and F. Hoffman-La Roche Ltd. |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |
Upfront non-refundable payment and certain additional payments received | $ 34,500,000 |  |  |  |  |  |  |
Additional upfront non-refundable amount received under previous agreement | $ 11,000,000.0 |  |  |  |  |  |  |
Number of designated targets | Target | 10 |  |  |  |  |  |  |

X
- Definition Additional upfront non-refundable amount received under previous agreement. + References No definition available. + Details
Name: | arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement
Namespace Prefix: | arvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of maximum designated targets. + References No definition available. + Details
Name: | arvn_NumberOfMaximumDesignatedTargets
Namespace Prefix: | arvn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research collaboration and license agreements. + References No definition available. + Details
Name: | arvn_ResearchCollaborationAndLicenseAgreementsLineItems
Namespace Prefix: | arvn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sale of stock, fair value of shares sold. + References No definition available. + Details
Name: | arvn_SaleOfStockFairValueOfSharesSold
Namespace Prefix: | arvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_IncreaseDecreaseInContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedPerTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=arvn_BayerAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_OptionExercisedToLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_SubstitutionTargetPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |